abstract |
The present invention relates to the use of an NRF2 activator to treat respiratory diseases. In particular, the present invention relates to the treatment of respiratory diseases, in a mammal, in which related organ failure accompanied by accumulation of alveolar fluid, cough, wheezing, dyspnea, hyperpnea, hypoxemia and pulmonary inflammation has occurred. |